MLTX in the 13F filings
Moonlake Immunotherapeutics · CUSIP 61559X104
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 18 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 26
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 0 listed it in both
- Shares listed
- 15,482,081
- combined, among listed positions
- Reported value
- $289m
- combined, at the quarter end
Among the 91 comparable managers: 14 buyers (opened or added shares) and 13 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,108,524.
Managers listing MLTX in Q1 2026
26 of 26 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 3,451,628 shares now+1,355,640
- Citadel Advisors LLCexisting position · 1,323,728 shares now+942,838
- Holocene Advisors LPnew position · 600,000 shares now+600,000
- Point72 Asset Management LPexisting position · 1,368,518 shares now+596,018
- Two Sigma Investments LPexisting position · 1,122,312 shares now+337,501
Reductions
- Jane Street Group LLCexisting position · 453,625 shares now-1,228,523
- Balyasny Asset Management LLCexisting position · 1,065,610 shares now-505,461
- Schonfeld Strategic Advisors LLCexisting position · 28,682 shares now-293,579
- Millennium Management LLCexisting position · 576,092 shares now-226,630
- Susquehanna International Group LLPexisting position · 341,424 shares now-207,812
New positions and exits
New (6)
- Holocene Advisors LP$11m
- Invesco Ltd$2.6m
- Marshall Wace LLP$2.1m
- Arrowstreet Capital LP$1.3m
- Acadian Asset Management LLC$305k
- Winton Group Ltd$292k
Exited (1)
- Woodline Partners LPwas $648k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2023 | 3 | $12m | n.a. | n.a. |
| Q3 2023 | 5 | $155m | n.a. | n.a. |
| Q4 2023 | 7 | $257m | 6 | 1 |
| Q1 2024 | 4 | $116m | 3 | 3 |
| Q2 2024 | 3 | $130m | 3 | 0 |
| Q3 2024 | 4 | $300m | 3 | 1 |
| Q4 2024 | 4 | $350m | 3 | 0 |
| Q1 2025 | 3 | $44m | 1 | 2 |
| Q2 2025 | 1 | $15m | 1 | 0 |
| Q3 2025 | 1 | $6.9m | 1 | 0 |
| Q1 2026 | 2 | $75m | 14 | 13 |
| Q2 2026 | 2 | $65m | 13 | 14 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MLTX and LLY →MLTX and JNJ →MLTX and VRTX →Choose a stock to compare with MLTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MLTX, latest filings →Back to the 13F Explorer →